Related Experiment Video
Updated: Jun 4, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with
J Ian Stuart1, Michael A John, Sue Milburn
1Department of Microbiology, London Health Sciences Centre, London, Ontario, Canada.
Abstract:
Coagulase-negative staphylococci (CoNS) have emerged as important nosocomial pathogens. CoNS resistance to meticillin and other semisynthetic penicillins is now common. Elevated vancomycin minimal inhibitory concentrations (MICs) have been reported and are associated with worse treatment outcomes. Several newer antibiotics have recently become available for the treatment of Gram-positive infections. The purpose of this study was to assess the in vitro activity of telavancin, daptomycin, linezolid and tigecycline in comparison with oxacillin and vancomycin against 653 non-duplicate clinical isolates of CoNS by the agar dilution method. The greatest variability in MIC was observed for oxacillin. Presence of the mecA gene conferred higher MICs for oxacillin but did not influence MICs to all other antibiotics tested. Telavancin tended to have MICs that were 1-2 dilutions lower than vancomycin. Daptomycin had good activity against all isolates. Staphylococcus haemolyticus, Staphylococcus hominis subsp. novobiosepticus, Staphylococcus saprophyticus, Staphylococcus schleiferi and Staphylococcus simulans were the most daptomycin-susceptible CoNS species tested. The validity of the agar dilution method for daptomycin was confirmed, with >90% isolates having MICs that were within 1 dilution of parallel Etest results. Within-species MIC variation was most restricted for linezolid and tigecycline, with the exception of Staphylococcus epidermidis and Staphylococcus haemolyticus that demonstrated higher overall MICs to tigecycline.
Insights
Newer antibiotics like telavancin and daptomycin show promising in vitro activity against challenging coagulase-negative staphylococci (CoNS) infections, offering alternatives to older drugs with increasing resistance.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Coagulase-negative staphylococci (CoNS) are significant causes of hospital-acquired infections.
- Increasing resistance to methicillin and other penicillins, alongside elevated vancomycin MICs, complicates CoNS treatment.
- Emergence of novel antibiotics necessitates evaluation against prevalent pathogens.
Purpose of the Study:
- To evaluate the in vitro efficacy of telavancin, daptomycin, linezolid, and tigecycline.
- To compare these newer agents against oxacillin and vancomycin.
- To assess activity against a large collection of clinical CoNS isolates.
Main Methods:
- Agar dilution method used for susceptibility testing.
- Tested 653 non-duplicate clinical isolates of CoNS.
- Validated daptomycin testing with parallel Etest results.
Main Results:
- Oxacillin exhibited the highest MIC variability; mecA gene presence increased oxacillin MICs.
- Telavancin showed lower MICs than vancomycin (1-2 dilutions).
- Daptomycin demonstrated broad activity, particularly against specific CoNS species; linezolid and tigecycline had restricted within-species MIC variation, except for certain species with higher tigecycline MICs.
Conclusions:
- Telavancin, daptomycin, linezolid, and tigecycline represent viable therapeutic options for CoNS infections.
- Daptomycin exhibits potent activity across various CoNS species.
- Understanding antibiotic susceptibility patterns is crucial for effective CoNS management.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Antimicrobial Effectiveness
Inhibitors of Gram-positive Cell Wall Synthesis
Development of Antibiotic Resistance
Antibiotic Selection
